Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Novo Nordisk is under fresh scrutiny as analysts adjust their price targets, with a fair value estimate moving from DKK 309.77 to DKK 316.91. This shift reflects a broader rethink of growth and risk assumptions, as analysts weigh more cautious revenue expectations against their updated view of what the stock might be worth. As you read on, you will see how to interpret these changing targets and what they could mean for your own view of Novo Nordisk.
Stay updated as the Fair Value for Novo Nordisk shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.
What Wall Street Has Been Saying 🐂 Bullish Takeaways
Across the recent research, several large banks and brokers have been willing to lift fair value estimates. This supports the move in Novo Nordisk’s internal fair value range from DKK 309.77 to DKK 316.91 as a measured, research backed adjustment rather than an outlier view.
Analysts updating their models tend to frame higher fair value estimates as a reflection of what they see as resilient execution and clearer visibility on Novo Nordisk’s growth drivers, even while acknowledging more cautious revenue assumptions in the near term.
The willingness to refine targets instead of stepping back from coverage signals that Novo Nordisk remains firmly on the radar for institutions that are actively reassessing risk and reward across the healthcare sector.
🐻 Bearish Takeaways
The shift in fair value to DKK 316.91 is incremental rather than dramatic. This suggests analysts are tempering expectations and building in more conservative revenue paths for Novo Nordisk instead of assuming a straight line of expansion.
Commentary around the new target implies that valuation already reflects a good amount of optimism. Any stumble in execution or change in the revenue mix could leave less room for upside before analysts revisit their assumptions again.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
CPSE:NOVO B 1-Year Stock Price Chart
We’ve flagged 4 risks for Novo Nordisk. See which could impact your investment.
What’s in the News
Medicare has launched a temporary GLP-1 Bridge program that includes Novo Nordisk’s Wegovy injections and tablets for eligible U.S. seniors through 2027, widening access to its obesity treatments in that market.
The UK regulator has approved Novo Nordisk’s Wegovy oral GLP-1 pill for weight management, the first oral GLP-1 pill for obesity in Europe, adding a non injectable option alongside the existing injectable Wegovy.
Novo Nordisk is running a DKK 15b share buyback over 12 months and had repurchased about 23.98m B shares for more than DKK 6.2b at an average price near DKK 270 per share as of 10 July 2026. Around 0.9% of its share capital is held as treasury shares.
Clinical data for the Wegovy pill, including OASIS 4 analyses showing double digit average weight loss, and a positive CHMP opinion recommending EU marketing authorisation for once daily oral semaglutide 25 mg with cardiovascular outcomes data on the label, continue to keep the oral GLP-1 profile in focus.
Story Continues
How This Changes the Fair Value For Novo Nordisk
Fair value estimate adjusted from DKK 309.77 to DKK 316.91.
Revenue outlook shifted from 1.08% growth to a 0.22% decline in DKK terms.
Expected net profit margin moved from 32.34% to 31.50%.
Future P/E multiple changed from 15.59x to 16.05x on forward earnings.
Discount rate used in models increased from 5.24% to 5.38%.
Never Miss an Update: Follow The Narrative
Narratives link Novo Nordisk’s business story to the analyst forecasts and fair value behind the numbers. They update automatically as new data, guidance, and news are factored into the outlook.
Head over to the Simply Wall St Community and follow the Narrative on Novo Nordisk to stay up to date on:
How low current penetration of GLP-1 treatments in diabetes and obesity leaves a large pool of potential patients for Novo Nordisk’s therapies.
What expanding access, product launches such as Wegovy in more countries, and new GLP-1 formats such as oral pills and implants could indicate for future demand.
Key risks from pricing pressure, generic and biosimilar competition, compounding of GLP-1 products, and rising costs that could affect margins and earnings stability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com